Notably, targeting phosphorylation modifications can alter PD-L1’s ubiquitination or acetylation status, consequently affecting its protein stability to ultimately modulate pancreatic cancer’s immunologic landscape. The gene discussed is CD274; the disease is pancreatic neoplasm.